Scientists at Zhengzhou University and affiliated organizations synthesized and optimized a series of thienopyridine indole derivatives leading to the identification of compound [I] as the lead tubulin polymerization inhibitor with broad-spectrum antiproliferative activity.
Shanghai Institute of Organic Chemistry has prepared and tested microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer, traumatic brain injury, multiple sclerosis, and Alzheimer’s, Huntington's and Parkinson's disease.
Ariel Scientific Innovations Ltd. has synthesized microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer.
Researchers from China Pharmaceutical University published data detailing the discovery and preclinical evaluation of novel tubulin polymerization inhibitors as potential anticancer agents.
Humanwell Healthcare (Group) Co. Ltd. has disclosed microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of anemia, asthma, atherosclerosis and rheumatoid arthritis, among others.
In efforts to design microtubule polymerization inhibitors with the ability to induce immunogenic cell death (ICD), investigators from China Pharmaceutical University have discovered novel isoquinoline analogues based on podophyllotoxin and diphyllin that act as dual tubulin polymerization and V-ATPase inhibitors.
Researchers from Baylor University and collaborators have described the synthesis and evaluation of a series of 6-aryl-3-aroyl-indole analogues acting as tubulin polymerization inhibitors aimed to be used as anticancer agents. Inhibitors of tubulin polymerization are promising antiproliferative agents and their interaction with the colchicine site is linked to its activity as vascular disrupting agents (VDAs).
Synthesis and optimization of substituted 2-amino[1,2,4]-triazolopyrimidines and related heterocycles by Wuyi University investigators has led to the identification of compound [I], and its water-soluble phosphate sodium salt prodrug, compound [II].
Researchers from China Pharmaceutical University have recently reported the discovery and preclinical characterization of a series of novel dihydroquinolin-4(1H)-one derivatives targeting the colchicine-binding site and intended for use as antitumor agents.
